Status:
COMPLETED
To Evaluate the Effect of Ginkgo Biloba Extract on Optic Nerve Head Perfusion Examined Using OCTA
Lead Sponsor:
Nova Scotia Health Authority
Conditions:
Glaucoma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Glaucoma is defined as progressive neuropathy of the optic nerve. It is an important cause of irreversible blindness worldwide. Lowering the intraocular pressure is the only proven treatment for this ...
Detailed Description
Glaucoma is defined as progressive neuropathy of the optic nerve. It is an important cause of irreversible blindness worldwide. Lowering the intraocular pressure is the only proven treatment for this ...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Early open angle glaucoma based on gonioscopy, clinical assessment of optic nerve head, OCT optic nerve and Humphrey Visual Field 24-2 (MD \< -10dB) and positive Glaucoma Hemifield Test
- BCVA equal or better than 6/12
- Written consent
- Ability to comply with treatment intervention for duration of study
Exclusion
- Younger than 18 years of age
- Angle closure glaucoma or secondary open angle glaucoma
- Refraction exceeding 6D spherical equivalent or 3D astigmatism
- Severe corneal, lens, vitreous media opacity limit signal strength of OCTA imaging
- Severe open angle glaucoma with visual field mean deviation worse than -10dB
- Inability to comply to treatment intervention (e.g. swallowing difficulty)
- History of ocular disease affecting ocular perfusion (e.g. CRAO, CRVO, diabetic retinopathy, ocular ischemic syndrome, ischemic optic neuropathy)
- History of glaucoma surgery
- Those taking anticoagulant therapy
- Those with blood disorders or diabetes
- Women who were pregnant, planning to become pregnant, or who were breast-feeding,
- Patients with a history of seizures or who were currently taking anti-convulsant medication, and
- Taking any drugs that may interact with GBE
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2024
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04846179
Start Date
May 1 2021
End Date
March 31 2024
Last Update
August 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nova Scotia Health
Halifax, Nova Scotia, Canada, B3H 4R2